Like_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":147753795,"tweetId":"147753795","gmtCreate":1626392727417,"gmtModify":1633927254686,"author":{"id":3582969710070724,"idStr":"3582969710070724","authorId":3582969710070724,"authorIdStr":"3582969710070724","name":"OO_898","avatar":"https://static.tigerbbs.com/9fb3c360d5d7711641a868a144192fc7","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":23,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Like&nbsp;</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/147753795","repostId":1140595356,"repostType":4,"repost":{"id":"1140595356","pubTimestamp":1626387586,"share":"https://www.laohu8.com/m/news/1140595356?lang=&edition=full","pubTime":"2021-07-16 06:19","market":"us","language":"en","title":"Why Moderna Stock Is Hitting Another Record High Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1140595356","media":"Motley Fool","summary":"The vaccine stock benefited from two positive developments.\n\nKey Points\n\nA Wall Street analyst raise","content":"<blockquote>\n The vaccine stock benefited from two positive developments.\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>A Wall Street analyst raised his price target for Moderna.</li>\n <li>A top European official also stated that a recommendation on authorization for Moderna's COVID-19 vaccine would probably be made by late next week.</li>\n</ul>\n<p><b>What happened</b></p>\n<p>Shares of<b>Moderna</b>(NASDAQ:MRNA)were jumping 4.3% as of 11:10 a.m. EDT on Thursday, hitting another record high for the stock. The bump came after Michael Yee, an analyst at<b>Jefferies</b>, increased his price target on the stock from $170 to $250.</p>\n<p>Also, Dr. Marco Cavaleri, the European Medicines Agency (EMA) head of biological health threats and vaccines strategy, stated in a press conference that a committee would likely finalize a decision on recommending authorization for Moderna's COVID-19 vaccine in children by the end of next week.</p>\n<p><b>So what</b></p>\n<p>Jefferies' higher price target for thevaccine stockreflected expectations of increased sales for Moderna's COVID-19 vaccine this year. Yee now looks for the company to up its full-year revenue guidance to $21 billion. It previously projected sales of $19.2 billion.</p>\n<p>The EMA's decision on authorization of the vaccine in immunizing children ages 12 to 17 could play a key role in driving higher sales. Although there are many more adults in the European Union than children, the pediatric market presents a big opportunity for the company.</p>\n<p>Neither of these news items, however, were compelling reasons for Moderna's shares to move higher. Jefferies' price target is actually lower than its current share price. Also, Cavaleri's comments about the pending decision by an expert committee didn't provide any hints as to what the recommendation would be.</p>\n<p><b>Now what</b></p>\n<p>The most important thing to watch with Moderna in the near term isn't the EMA committee announcement next week. Instead, it's the company's second-quarter update scheduled for Aug. 5. Moderna is likely to boost its full-year sales outlook in that update.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Is Hitting Another Record High Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Is Hitting Another Record High Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 06:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/15/why-moderna-stock-is-hitting-another-record-high-t/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The vaccine stock benefited from two positive developments.\n\nKey Points\n\nA Wall Street analyst raised his price target for Moderna.\nA top European official also stated that a recommendation on ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/15/why-moderna-stock-is-hitting-another-record-high-t/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/07/15/why-moderna-stock-is-hitting-another-record-high-t/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140595356","content_text":"The vaccine stock benefited from two positive developments.\n\nKey Points\n\nA Wall Street analyst raised his price target for Moderna.\nA top European official also stated that a recommendation on authorization for Moderna's COVID-19 vaccine would probably be made by late next week.\n\nWhat happened\nShares ofModerna(NASDAQ:MRNA)were jumping 4.3% as of 11:10 a.m. EDT on Thursday, hitting another record high for the stock. The bump came after Michael Yee, an analyst atJefferies, increased his price target on the stock from $170 to $250.\nAlso, Dr. Marco Cavaleri, the European Medicines Agency (EMA) head of biological health threats and vaccines strategy, stated in a press conference that a committee would likely finalize a decision on recommending authorization for Moderna's COVID-19 vaccine in children by the end of next week.\nSo what\nJefferies' higher price target for thevaccine stockreflected expectations of increased sales for Moderna's COVID-19 vaccine this year. Yee now looks for the company to up its full-year revenue guidance to $21 billion. It previously projected sales of $19.2 billion.\nThe EMA's decision on authorization of the vaccine in immunizing children ages 12 to 17 could play a key role in driving higher sales. Although there are many more adults in the European Union than children, the pediatric market presents a big opportunity for the company.\nNeither of these news items, however, were compelling reasons for Moderna's shares to move higher. Jefferies' price target is actually lower than its current share price. Also, Cavaleri's comments about the pending decision by an expert committee didn't provide any hints as to what the recommendation would be.\nNow what\nThe most important thing to watch with Moderna in the near term isn't the EMA committee announcement next week. Instead, it's the company's second-quarter update scheduled for Aug. 5. Moderna is likely to boost its full-year sales outlook in that update.","news_type":1},"isVote":1,"tweetType":1,"viewCount":47,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/147753795"}